ArticleEuropean heart journal. Acute cardiovascular care2023
Catheter-directed mechanical aspiration thrombectomy in a real-world pulmonary embolism population: a multicenter registry.
Article in European heart journal. Acute cardiovascular care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Outcomes of catheter-directed mechanical thrombectomy in patients with cancer-associated pulmonary embolism: a multicenter, prospective registry.Research and practice in thrombosis and haemostasis · 2026Observational
- Comparative Outcomes of Ultrasound-Assisted Thrombolysis and Mechanical Thrombectomy in Intermediate-High-Risk Pulmonary Embolism.Journal of clinical medicine · 2026Article
- Electrocardiographic signs to differentiate between chronic thromboembolic pulmonary hypertension and intermediate-high risk acute pulmonary embolism.Scientific reports · 2026Article
- Complications of catheter-directed interventions in acute pulmonary embolism: a narrative expert review with guidance on management.Cardiovascular diagnosis and therapy · 2026Review
- Intraprocedural Management of Pulmonary Embolism Patients Undergoing Transcatheter Treatment, and Ventilatory and Cardiac Support.Interventional cardiology (London, England) · 2026Review
- Percutaneous Reperfusion Therapies vs. Anticoagulation in Patients With Acute Intermediate-High-Risk Pulmonary Embolism: The PRETHA Randomized Clinical Trial.Pulmonary circulation · 2026Article
- Periprocedural Results and Right Ventricular Outcomes of Computer Assisted Vacuum Thrombectomy Treatment of Acute Pulmonary Embolism: Interim Analysis of 300 Patients From the STRIKE-PE Study.Journal of the American Heart Association · 2025Observational
- Multicentre, real-world data of next-generation computer-assisted vacuum aspiration thrombectomy in acute pulmonary embolism.Respiratory research · 2025Observational
- Continuous mechanical aspiration thrombectomy for STEMI with high thrombus burden.Cardiology journal · 2025Article
- Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care.Journal of clinical medicine · 2024Review
- Research progress in interventional therapy for acute intermediate-high-risk and high-risk pulmonary embolism.Journal of thoracic disease · 2024Review
- Endovascular treatments of acute pulmonary embolism in the post-fibrinolytic era: an up-to-date review.Insights into imaging · 2024Review
- Catheter Interventions for Pulmonary Embolism: Mechanical Thrombectomy Versus Thrombolytics.Methodist DeBakey cardiovascular journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHigh- (HR) and intermediate-high risk (IHR) pulmonary embolisms (PEs) are related to high early mortality and long-term sequelae. We aimed to describe clinical outcomes and adverse events in IHR and HR pulmonary embolism (PE) treated with catheter-directed mechanical thrombectomy (CDMT) in a real-world population. METHODS AND
resultsThis study is a multicenter, prospective registry enrolling 110 PE patients treated with CDMT between 2019 and 2022. The CDMT was performed using the 8F Indigo (Penumbra, Alameda, CA, USA) system bilaterally in pulmonary arteries (PAs). The primary safety endpoints included device or PE-related death during the 48-h after CDMT, procedure-related major bleeding, or other major adverse events. Secondary safety outcomes were all-cause mortality during hospitalization or the follow-up. The primary efficacy outcomes were the reduction of PA pressures and change in the right-to-left ventricular (RV/L) ratio assessed in the imaging 24-48 h after the CDMT.71.8% of patients had IHR PE and 28.2% HR PE. 11.8% of patients had a failure and 34.5% had contraindications to thrombolysis, and 2.7% had polytrauma. There was 0.9% intraprocedural death related to RV failure and 5.5% deaths within the first 48 h. CDMT was complicated by major bleeding in 1.8%, pulmonary artery injury in 1.8%, and ischaemic stroke in 0.9%. Immediate haemodynamic improvements included a 10.4 ± 7.8 mmHg (19.7%) drop in systolic PAP (P < 0.0001), a 6.1 ± 4.2 mmHg (18.8%) drop in mean PAP, and 0.48 ± 0.4 (36%) drop in RV/LV ratio (P < 0.0001).
conclusionThese observational findings suggest that CDMT may improve hemodynamics with an acceptable safety profile in patients with IHR and HR PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.